This study is for adults aged 40-80 with chronic obstructive pulmonary disease (COPD), a lung disease that makes breathing hard. It focuses on those with an eosinophilic phenotype, which means they have high levels of a type of white blood cell called eosinophils. The study will compare a treatment called lunsekimig given by injection under the skin to a placebo, which is a fake treatment that looks like the real one but has no effect.

Participants will first go through a screening period lasting up to 4 weeks, followed by the main treatment for about 48 weeks, and finally a follow-up period of about 8 weeks. That's a total of up to 60 weeks.

• Length of Study: Up to 60 weeks total.
• Treatment: Injections of either lunsekimig or placebo for 48 weeks.
• Eligibility: Must be diagnosed with COPD, meet certain lung function criteria, and have a history of smoking.

If you have other lung diseases, asthma, or certain other health conditions, you may not qualify. Always talk to your doctor before joining a study.